aceBias in medical AI: Implications for clinical decision-making
Biases in medical artificial intelligence (AI) arise and compound throughout the AI lifecycle. These biases can have significant clinical consequences, especially in applications that involve clinical decision-making. Left unaddressed, biased medical AI can lead to substandard clinical decisions and the perpetuation and exacerbation of longstanding healthcare disparities. We discuss potential biases that can arise at different stages in the AI development pipeline and how they can affect AI algorithms and clinic…
Towards an Artificial Brain - David Cox by World Economic Forum. CC BY 3.0 · https://creativecommons.org/licenses/by/3.0
This 2024 peer-reviewed discussion examines how biases arise and compound throughout the medical AI lifecycle, from data features and labels through model development, evaluation, deployment, and publication, and how those biases affect clinical decision-making.
It matters because unaddressed bias risks substandard decisions and widening disparities, with models performing worse for underrepresented groups and outside their training populations. Uncertainty remains about which mitigation strategies will reliably ensure equitable benefit without prospective clinical trial validation.
- Bias can enter at data features and labels, model development and evaluation, deployment, and publication stages of medical AI.
- Insufficient sample sizes for certain patient groups and nonrandomly missing data such as diagnosis codes and social determinants of health produce biased model behavior.
- Expert-annotated training labels may reflect implicit cognitive biases or substandard care practices, while overreliance on performance metrics can obscure bias.
- Authors recommend large diverse datasets, statistical debiasing, thorough evaluation, interpretability, standardized bias reporting, and rigorous clinical trial validation before implementation.
Biased medical AI can lead to substandard clinical decisions and perpetuate healthcare disparities, with performance deteriorating differentially across patient subgroups when deployed outside training cohorts.
The rundown
The article traces bias across the full AI lifecycle, from data collection where small samples for certain groups and missing findings like diagnosis codes and social determinants skew features, to labels where expert annotation may encode cognitive bias or substandard care.
During development and evaluation, overreliance on aggregate performance metrics can hide subgroup failures, and models often degrade when applied outside the training cohort, with differential impact. Deployment introduces user-interaction bias, and publication patterns shape future priorities.
Mitigation discussed includes collecting large and diverse datasets, statistical debiasing methods, thorough evaluation, emphasis on interpretability, standardized bias reporting and transparency, and rigorous validation through clinical trials prior to real-world clinical use.
Sources
- Peer-reviewedPLOS Digital Health2024-11-07
How should this claim be treated?
The debate